NANTES, FRANCE--(Marketwire - June 23, 2010) -
VIVALIS (NYSE Euronext: VLS), a
biopharmaceutical company, announced today that its research and
development teams have moved into its new facility in Saint-Herblain
Nantes, France.
This new 3,300 m² (35,520 ft2) facility is dedicated to R&D activities
and support functions. The project was initiated at the end of 2008 and
integrates all research teams onto the same site, which is adjacent to
Vivalis' existing 1,500 m² (16,150 ft2) cGMP bioproduction facility,
completed in 2005.
The new building houses state-of-the-art equipment used for biologics
research and the construction has been governed by an environmentally
responsible approach, being designed to use 25% less energy than our
current bioproduction facility completed five years ago. With a total
investment of 6.5M€ as budgeted (5.5M€ for the facility and
approximately 1M€ for equipment), the facility was financed by state
and local entities (DIACT, Region Pays de Loire, Departement of Loire
Atlantique and Nantes Métropole for a total of 2.4M€), bank loans
(2.5M€) and VIVALIS (1.6M€).
With this new facility VIVALIS will be able to accelerate its development
projects while improving the working environment and conditions of its
employees.
"We are very pleased to move into these new facilities that give us the
ability to regroup the teams that were spread over several locations
following the rapid expansion of our workforce. We are very proud of being
able to offer our researchers optimal conditions to conduct their research.
We now have two locations in Nantes totaling over 4,800 m² (51,700
ft2) located on one site and dedicated to research and biomanufacturing,"
said Franck Grimaud, CEO, and Majid Mehtali, CSO, co-managers of VIVALIS.
**********************
Next financial press release:
21 July 2010, after NYSE Euronext market closing: Second quarter 2010
revenues
About VIVALIS (www.vivalis.com)
VIVALIS (Euronext code: VLS) is a biopharmaceutical company that provides
innovative cell-based solutions to the pharmaceutical industry for the
manufacture of vaccines and proteins, and develops drugs for the prevention
and treatment of viral diseases. VIVALIS' expertise and intellectual
property are exploited in three main areas:
1. VIVALIS offers research and commercial licenses for its EB66® cell
line, derived from duck stem cells, to pharmaceutical and biotechnology
companies for the production of vaccines and monoclonal antibodies. VIVALIS
receives upfront fees, milestone payments and royalties on licensees' net
sales.
2. Through the Humalex® platform, VIVALIS offers customers solutions for
the generation, development and production of human antibodies. VIVALIS
receives upfront fees, milestone payments and royalties on licensees' net
sales.
3. A portfolio of proprietary products in the area of vaccines and anti-
viral molecules (hepatitis C).
Based in Nantes (France), VIVALIS was founded in 1999 by the Grimaud group
(ca. 1,500 employees), the second largest group worldwide in animal genetic
selection. VIVALIS has established more than 30 partnerships and licenses
with world leaders in this sector, including Sanofi Pasteur,
GlaxoSmithKline, Merck, CSL, Kaketsuken, Merial, Intervet, SAFC
Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES and
LYON BIOPOLE bio-clusters.
+-------------------------+-+
|VIVALIS | |
+-------------------------+-+
|Listed on Euronext Paris | |
|– Compartment C of NYSE | |
|Euronext | |
+-------------------------+-+
|Reuters: VLS.PA – | |
|Bloomberg: VLS FP | |
+-------------------------+-+
|Included in NYSE | |
|Euronext’s SBF 250, CAC | |
|Small 90 and Next Biotech| |
|indexes | |
+-------------------------+-+
+-------------------------+-+
Contacts
VIVALIS
Franck Grimaud, CEO
Email: investors@vivalis.com
NewCap
Financial communications agency
Steve Grobet / Pierre Laurent
Tel.: +33 (0) 1 44 71 94 91
Email: vivalis@newcap.fr
This document contains forward-looking statements and comments on the
company's objectives and strategies. No guarantee can be given as to any of
the events anticipated by the forward-looking statements, which are subject
to inherent risks, including the risk factors described in the company's
document de référence, changes in economic conditions, the
financial markets or the markets in which the company operates.
This information is provided by HUGIN
